Therapeutic Advances in Systemic Lupus Erythematosus: Targeting T Follicular Helper Cells

Area of Science:

• Immunology
• Rheumatology
• Autoimmune Diseases

Background:

• Systemic lupus erythematosus (SLE) is a chronic autoimmune disease causing widespread inflammation and organ damage.
• Some SLE patients show poor response to standard treatments.
• Dysregulated T follicular helper (Tfh) cell responses are key in SLE development.

Purpose of the Study:

• To review the role of Tfh cells in SLE pathogenesis.
• To summarize therapeutic targets and drugs for Tfh-directed strategies.
• To highlight the translational potential of targeting Tfh cells in SLE.

Main Methods:

• Comprehensive literature review of studies on Tfh cells in SLE.
• Focus on pathogenic mechanisms.
• Analysis of therapeutic strategies targeting Tfh cell surface molecules, cytokines, transcription factors, epigenetic, and metabolic pathways.

Main Results:

• Targeting Tfh cell surface molecules, cytokines, and transcription factors shows therapeutic promise.
• Epigenetic and metabolic pathway targeting are emerging strategies.
• Innovative therapies like bispecific antibodies and CAR-T cell therapies are promising for Tfh intervention.

Conclusions:

• Tfh cells are central to SLE pathogenesis and are a viable therapeutic target.
• Tfh-directed strategies can advance precision medicine through immune profiling and combination therapies.
• These approaches provide a basis for overcoming current treatment challenges in SLE.